Key Points
- CeriBell director Joseph Michael Taylor sold 5,500 shares on June 11 at an average price of $18.41, totaling about $101,255 and reducing his stake by 8.2%.
- The company recently reported quarterly earnings of ($0.52) per share, missing estimates, while revenue of $26.49 million slightly beat expectations; analysts now expect a full-year loss of $1.69 per share.
- Analyst sentiment remains Moderate Buy overall, with a consensus target price of $22.20, even as some firms trimmed targets or downgraded ratings.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Joseph Michael Taylor sold 5,500 shares of CeriBell stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $18.41, for a total transaction of $101,255.00. Following the sale, the director directly owned 61,573 shares in the company, valued at approximately $1,133,558.93. This trade represents a 8.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
CeriBell Price Performance
CeriBell stock opened at $18.59 on Tuesday. The company has a fifty day simple moving average of $18.98 and a 200-day simple moving average of $19.71. The firm has a market capitalization of $705.30 million, a price-to-earnings ratio of -11.40 and a beta of 0.85. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $24.33.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The business had revenue of $26.49 million during the quarter, compared to analysts' expectations of $26.09 million. On average, equities analysts anticipate that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.
Analyst Ratings Changes
CBLL has been the topic of several recent research reports. Canaccord Genuity Group lowered their target price on CeriBell from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, May 12th. Weiss Ratings downgraded CeriBell from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $22.20.
Check Out Our Latest Stock Report on CeriBell
Hedge Funds Weigh In On CeriBell
Institutional investors have recently bought and sold shares of the company. Strs Ohio acquired a new position in CeriBell in the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company's stock worth $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of CeriBell during the 3rd quarter valued at approximately $33,000. CWM LLC raised its position in shares of CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company's stock valued at $40,000 after buying an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter.
About CeriBell
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
